| Diabetes (n=387) | CKD (n=103) | Chronic CVD (n=227) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | OM 40/ AML 10 mg | OM 40/ HCTZ 25 mg | AML 10/ HCTZ 25 mg | OM 40/ AML 10/ HCTZ 25 mg | OM 40/ AML 10 mg | OM 40/ HCTZ 25 mg | AML 10/ HCTZ 25 mg | OM 40/ AML 10/ HCTZ 25 mg | OM 40/ AML 10 mg | OM 40/ HCTZ 25 mg | AML 10/ HCTZ 25 mg | OM 40/ AML 10/ HCTZ 25 mg |
 | (n=100) | (n=99) | (n=92) | (n=96) | (n=29) | (n=25) | (n=29) | (n=20) | (n=56) | (n=61) | (n=55) | (n=55) |
Age, mean (SD), yrs | 59.7 (8.9) | 60.3 (8.7) | 56.5 (9.4) | 58.1 (9.4) | 71.0 (7.8) | 71.5 (9.4) | 69.4 (9.5) | 68.1 (10.0) | 60.2 (11.2) | 61.1 (9.8) | 58.2 (11.0) | 58.6 (10.9) |
Male, n (%) | 60 (60.0) | 54 (54.5) | 52 (56.5) | 51 (53.1) | 9 (31.0) | 10 (40.0) | 10 (34.5) | 5 (25.0) | 40 (71.4) | 38 (62.3) | 34 (61.8) | 39 (70.9) |
Ethnicity | Â | |||||||||||
Hispanic/Latino, n (%) | 21 (21.0) | 18 (18.2) | 13 (14.1) | 15 (15.6) | 1 (3.4) | 2 (8.0) | 3 (10.3) | 2 (10.0) | 8 (14.3) | 5 (8.2) | 7 (12.7) | 8 (14.5) |
Race | Â | |||||||||||
White, n (%) | 72 (72.0) | 73 (73.7) | 58 (63.0) | 67 (69.8) | 18 (62.1) | 19 (76.0) | 21 (72.4) | 13 (65.0) | 40 (71.4) | 45 (73.8) | 37 (67.3) | 35 (63.6) |
Black, n (%) | 26 (26.0) | 24 (24.2) | 29 (31.5) | 25 (26.0) | 9 (31.0) | 5 (20.0) | 7 (24.1) | 6 (30.0) | 16 (28.6) | 16 (26.2) | 18 (32.7) | 17 (30.9) |
Obesity, n (%)* | 77 (77.0) | 74 (74.7) | 71 (77.2) | 73 (76.0) | 9 (31.0) | 2 (8.0) | 7 (24.1) | 6 (30.0) | 32 (57.1) | 40 (65.6) | 35 (63.6) | 33 (60.0) |
Hypertension duration, mean (SD), y | 12.8 (9.6) | 13.2 (10.5) | 11.2 (9.6) | 10.7 (9.8) | 12.1 (8.0) | 14.0 (10.0) | 13.0 (9.3) | 14.8 (14.4) | 12.0 (8.0) | 15.0 (12.3) | 12.9 (9.9) | 13.3 (11.0) |
Baseline BP, mean (SD), mm Hg | 172.2/98.6 (13.5/7.5) | 173.1/97.8 (14.7/7.6) | 170.7/99.3 (13.6/6.7) | 170.7/98.3 (16.0/6.9) | 174.4/96.4 (12.5/8.8) | 172.2/96.0 (11.6/7.6) | 172.9/97.4 (17.1/6.6) | 173.8/96.6 (16.5/6.5) | 173.4/101.0 (16.2/10.6) | 172.8/99.3 (11.7/9.3) | 174.2/100.8 (16.7/7.1) | 171.7/100.4 (11.0/9.1) |